| Gerald R Gorman, MD | |
|
680 Centre St, Brockton, MA 02302-3308 | |
| (508) 941-7400 | |
| (508) 941-6200 |
| Full Name | Gerald R Gorman |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 680 Centre St, Brockton, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194756403 | NPI | - | NPPES |
| 1200283 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 214473 (Massachusetts) | Primary |
| Entity Name | Delphi Healthcare Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003075029 PECOS PAC ID: 9537229661 Enrollment ID: O20081119000839 |
News Archive
HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has completed enrollment in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.
There are more bacteria living on our skin and in our gut than cells in our body. We need them. But until now no-one knew how the immune system could tell that these bacteria are harmless.
The red, swollen and painful gums and bone destruction of periodontal disease could be effectively treated by beckoning the right kind of immune system cells to the inflamed tissues, according to a new animal study conducted by researchers at the University of Pittsburgh.
Pfizer Inc. today released detailed information about how and why the company works with a range of healthcare professionals and researchers to advance patient care and develop lifesaving medicines. The information reflects payments or exchanges of value received by licensed U.S. healthcare professionals who consulted with Pfizer about the development and marketing of new medicines and helped to educate other healthcare professionals about the safe and appropriate use of its products.
› Verified 2 days ago
| Entity Name | Keystone Hospitalist Services Of New York Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174068761 PECOS PAC ID: 3173655230 Enrollment ID: O20100726000212 |
News Archive
HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has completed enrollment in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.
There are more bacteria living on our skin and in our gut than cells in our body. We need them. But until now no-one knew how the immune system could tell that these bacteria are harmless.
The red, swollen and painful gums and bone destruction of periodontal disease could be effectively treated by beckoning the right kind of immune system cells to the inflamed tissues, according to a new animal study conducted by researchers at the University of Pittsburgh.
Pfizer Inc. today released detailed information about how and why the company works with a range of healthcare professionals and researchers to advance patient care and develop lifesaving medicines. The information reflects payments or exchanges of value received by licensed U.S. healthcare professionals who consulted with Pfizer about the development and marketing of new medicines and helped to educate other healthcare professionals about the safe and appropriate use of its products.
› Verified 2 days ago
| Entity Name | Keystone Medical Services Of Niagara Falls Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578815189 PECOS PAC ID: 1456503952 Enrollment ID: O20121207000458 |
News Archive
HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has completed enrollment in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.
There are more bacteria living on our skin and in our gut than cells in our body. We need them. But until now no-one knew how the immune system could tell that these bacteria are harmless.
The red, swollen and painful gums and bone destruction of periodontal disease could be effectively treated by beckoning the right kind of immune system cells to the inflamed tissues, according to a new animal study conducted by researchers at the University of Pittsburgh.
Pfizer Inc. today released detailed information about how and why the company works with a range of healthcare professionals and researchers to advance patient care and develop lifesaving medicines. The information reflects payments or exchanges of value received by licensed U.S. healthcare professionals who consulted with Pfizer about the development and marketing of new medicines and helped to educate other healthcare professionals about the safe and appropriate use of its products.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gerald R Gorman, MD 680 Centre St, Brockton, MA 02302-3308 Ph: (508) 941-7400 | Gerald R Gorman, MD 680 Centre St, Brockton, MA 02302-3308 Ph: (508) 941-7400 |
News Archive
HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has completed enrollment in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.
There are more bacteria living on our skin and in our gut than cells in our body. We need them. But until now no-one knew how the immune system could tell that these bacteria are harmless.
The red, swollen and painful gums and bone destruction of periodontal disease could be effectively treated by beckoning the right kind of immune system cells to the inflamed tissues, according to a new animal study conducted by researchers at the University of Pittsburgh.
Pfizer Inc. today released detailed information about how and why the company works with a range of healthcare professionals and researchers to advance patient care and develop lifesaving medicines. The information reflects payments or exchanges of value received by licensed U.S. healthcare professionals who consulted with Pfizer about the development and marketing of new medicines and helped to educate other healthcare professionals about the safe and appropriate use of its products.
› Verified 2 days ago
Luis E. Ortiz, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 680 Centre St, Brockton, MA 02302 Phone: 508-941-7000 | |
Dr. Stephen J Simon, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 680 Centre St, Brockton, MA 02302 Phone: 508-941-7000 | |
Grant Wei, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 680 Centre St, Dept. Of Emergency Medicine, Brockton, MA 02302 Phone: 508-941-7400 | |
Jacob Kallenberg, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 235 N Pearl St, Brockton, MA 02301 Phone: 508-427-3075 | |
Daniel Werzanski, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 680 Centre St, Brockton, MA 02302 Phone: 508-941-7000 | |
Laura A Griffin, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 680 Centre Street, Brockton Hospital, Brockton, MA 02302 Phone: 508-941-7000 | |
Dr. Richard S. Herman, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 235 North Pearl Street, Brockton, MA 02301 Phone: 508-427-3034 |